
Codex Labs to Exhibit at the National Eczema Association's Eczema Expo 2025
'Codex Labs is honored to be a Gold Sponsor of Eczema Expo 2025 and introduce our new inside-out approach for helping manage eczema to the community,' says founder and CEO Dr. Barbara Paldus. 'We are excited to share our innovative skin-gut-brain-biome solutions with all attendees.'
Eczema Expo 2025's theme this year is 'Back to School' and will feature networking opportunities, support group discussions, lecture sessions, companies and exhibitors showcasing products, organizations dedicated to the eczema community, and more. Children (ages 0-17) can also attend Expo Camp, which offers a safe environment for children with eczema to have fun while learning more about the condition and proper skincare.
Codex Labs is an exhibitor and sponsor of this year's Eczema Expo. Dr. Paldus will be attending the event and running the Codex Labs exhibit. She will present the latest clinical results from Codex Labs' research on the improvements achieved in eczema SCORAD, itch and insomnia with pre- and pro-biotic supplements, as well as the benefits derived for skin barrier integrity when L-histidine is combined with a novel M3 antioxidant.
'I am delighted to share not only our topicals, which have been clinically proven to reduce eczema SCORAD by 93% and itch by over 90% in 8 weeks, but also our supplements like Bia GutBuilder Prebiotic and Bia ClearSkin Probiotic that are designed to help address gut permeability and irritation that are often associated with eczema,' says Dr. Paldus. 'We believe that we are at the cusp of offering new alternatives to improve the lives of those who suffer from atopic dermatitis.'
Eczema Expo provides an opportunity for hundreds of caregivers, healthcare professionals, industry experts, and individuals with eczema to come together in support of a unified cause. Codex Labs is honored to participate in the event and looks forward to showcasing its products and findings.
Codex Labs invites all event guests to visit their exhibit to learn more about their latest skincare breakthroughs and receive samples of their eczema topicals and supplements.
Event Details:
Dates: July 24th to 27th, 2025
July 24th, 7:00 a.m. - 9:00 p.m. MT
July 25th, 6:45 a.m. - 9:00 p.m. MT
July 26th, 6:45 a.m. - 11:00 p.m. MT
July 27th, 6:45 a.m. - 2:00 pm MT
Location:
7500 E Doubletree Ranch Rd, Scottsdale, AZ, 85258
For more information about Codex Labs and its products, please visit www.codexlabscorp.com. If you are interested in learning more about Codex Labs' participation in Expo 2025, please contact annakate.womack@otterpr.com.
About Codex Labs:
Based in Silicon Valley and led by scientist Dr. Barb Paldus, Codex Labs is committed to creating highly effective, clinically proven, microbiome-supporting skin-gut-brain-biome solutions that contain potent, biotech-derived plant-based actives. Codex Labs' products focus on restoring/protecting the skin barrier, managing inflammation, and addressing skin conditions associated with aging, acne, eczema, and psoriasis. The brand has been heralded by integrative dermatologists and naturopathic doctors for creating the next generation of effective, vegan, cruelty-free, and sustainable plant-based solutions.
Media Contact
Company Name: Otter Public Relations
Contact Person: Anna Kate Womack
Email: Send Email
Phone: 7032323140
City: ORLANDO
State: FL
Country: United States
Website: www.otterpr.com

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBC
8 hours ago
- CBC
New study looks at teen loneliness and AI: Dr. Peter Lin
A recent study by Common Sense Media and the University of Chicago asked teens about their use of artificial intelligence. Dr. Peter Lin explains what the study showed and how AI is affecting the mental health of teenagers.


CBC
a day ago
- CBC
Expert discusses potential impact of Trump's demand to slash drug prices in U.S.
U.S. President Donald Trump has issued a direct warning to top pharmaceutical companies, demanding they slash drug prices. Mina Tadrous, an associate professor at the University of Toronto's Leslie Dan Faculty of Pharmacy, discusses concerns and how this could impact drug prices in Canada.


Globe and Mail
a day ago
- Globe and Mail
AstraZeneca's AZD3427 Study: A Potential Game-Changer for Heart Failure and Pulmonary Hypertension
AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca, in collaboration with Parexel International, is conducting a Phase IIb study titled A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Due to Left Heart Disease (WHO Group 2). The study aims to assess the efficacy of AZD3427 in reducing pulmonary vascular resistance in patients with heart failure and pulmonary hypertension over 24 weeks, highlighting its potential significance in treating these conditions. The intervention being tested is AZD3427, administered as a subcutaneous injection. It is designed to target pulmonary hypertension by reducing vascular resistance, with the study evaluating three different dose levels of the drug. The study follows a randomized, parallel assignment model with triple masking, involving participants, care providers, and investigators. Its primary purpose is treatment-focused, aiming to determine the optimal dosing strategy for AZD3427. The study began on April 24, 2023, with an estimated completion date in July 2025. These timelines are crucial for tracking the progress and potential market introduction of AZD3427. The outcome of this study could significantly impact AstraZeneca's market position, potentially boosting its stock performance if results are positive. Investors will be keenly watching for updates, especially in the context of competitive treatments for heart failure and pulmonary hypertension. The study is ongoing, with further details available on the ClinicalTrials portal.